NewAmsterdam Pharma Receives Positive European Medicines Agency Opinion for Obicetrapib Therapies

European Medicines Agency Recommendation for Obicetrapib Therapies

NewAmsterdam Pharma Company N.V., a Netherlands-based pharmaceutical company, disclosed in its July 24, 2026 announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for both Ubeslo® and Evlarco®. The positive committee opinion represents a key regulatory milestone in the European approval process for these obicetrapib-based cardiovascular therapies. The company stated that this recommendation came through a collaborative effort with the Menarini Group, indicating a partnership approach to bringing these treatments to European patients.

The positive opinion from the Committee for Medicinal Products for Human Use is typically a prerequisite step toward formal European marketing authorization. This committee, composed of experts from European Union member states, evaluates the safety, efficacy, and risk-benefit profile of new pharmaceutical treatments. The filing indicates that both the monotherapy formulation and the fixed-dose combination have cleared this critical evaluation stage, suggesting regulatory confidence in the clinical and manufacturing data presented for both products.

Ubeslo® and Evlarco® Product Profiles

The filing identifies two distinct obicetrapib formulations now advancing through the European regulatory pathway. Ubeslo® represents the monotherapy approach, offering obicetrapib as a standalone treatment option for eligible patients. Evlarco®, the combination product, pairs obicetrapib with ezetimibe in a fixed-dose combination, providing a dual-mechanism therapeutic approach. The announcement does not specify the indication or therapeutic area for these products, but the inclusion of ezetimibe in one formulation suggests cardiovascular or lipid metabolism applications, as ezetimibe is commonly used in cholesterol management therapies.

The development of both monotherapy and combination options allows for flexible treatment approaches depending on patient needs and clinical circumstances. The positive opinion covering both formulations simultaneously demonstrates that the European regulatory committee found both treatment strategies suitable for patient use. The company did not disclose additional details regarding dosing, patient populations, or clinical efficacy data in the filing.

Partnership with Menarini Group in Regulatory Process

NewAmsterdam Pharma's collaboration with the Menarini Group appears integral to this European regulatory advancement. The filing indicates that both entities are named as recipients of the positive committee opinion, suggesting a joint regulatory submission and shared responsibility for the European development and commercialization of these products. The Menarini Group is a significant pharmaceutical organization with established European presence and distribution capabilities, making this partnership strategically relevant for market access and implementation.

The involvement of an established European pharmaceutical partner may strengthen the pathway to formal marketing authorization and subsequent commercialization. Such partnerships typically involve defined roles in regulatory submissions, manufacturing, distribution, and market launch activities. The filing does not specify the detailed terms, financial arrangements, or specific responsibilities assigned to each partner within this collaborative framework.

Regulatory Timeline and Next Steps

The positive opinion from the Committee for Medicinal Products for Human Use represents an intermediate regulatory step toward European marketing authorization. Following this positive recommendation, the European Commission typically issues a formal decision on marketing authorization. The filing does not provide specific timelines for this final approval stage or indicate when European patients might gain access to these products if authorization is granted. Investors may be watching for subsequent announcements regarding the European Commission's formal decision timeline.

The regulatory pathway in Europe includes multiple checkpoints designed to ensure drug safety and efficacy before market launch. The company did not disclose whether this positive opinion applies to a standard or accelerated review pathway, nor did it provide information about ongoing post-approval monitoring requirements or any conditions attached to the positive opinion. Future disclosures would likely clarify the regulatory status and expected timeline for formal European authorization.

Market Access and Commercial Implications

A positive European regulatory opinion supports potential market access across European Union member states and other European Economic Area countries that recognize European Medicines Agency decisions. NewAmsterdam Pharma's regulatory progress in Europe may represent a significant commercial opportunity, particularly if these therapies address unmet treatment needs or offer advantages over existing alternatives. The dual formulation approach provides flexibility for healthcare systems and patients with different treatment requirements.

The filing does not disclose market sizing estimates, pricing strategies, or commercial launch timelines for either European market or other regions. It also does not specify whether these products have received regulatory approval in other jurisdictions such as the United States or whether parallel regulatory submissions are underway in other markets. Investors interested in the global commercial potential of Ubeslo® and Evlarco® may await additional announcements regarding non-European regulatory progress.

Clinical Development and Regulatory Confidence

The positive committee opinion indicates that NewAmsterdam Pharma and Menarini Group have submitted comprehensive clinical data demonstrating the safety and efficacy of both obicetrapib formulations to European regulatory standards. The Committee for Medicinal Products for Human Use's positive assessment suggests that the clinical evidence package met established thresholds for risk-benefit evaluation. The filing does not provide specific details regarding the clinical trials, patient populations studied, or efficacy endpoints that supported this positive recommendation.

A positive opinion from this expert committee typically reflects confidence in the quality of the manufacturing process, consistency of the product, and clinical relevance of the submitted data. The company did not disclose the size or scope of clinical programs evaluated, the geographic distribution of trial sites, or any safety signals or limitations identified during the review process. Such details would typically appear in the formal European Public Assessment Report released following final marketing authorization.

NewAmsterdam Pharma's Regulatory Strategy

NewAmsterdam Pharma's advancement of obicetrapib-based therapies through European regulatory channels demonstrates the company's commitment to bringing these cardiovascular treatments to patients in major pharmaceutical markets. The timing of this July 2026 announcement aligns with the company's broader development strategy for this therapeutic program. The company did not disclose information about other development programs, research pipelines, or future regulatory submissions planned for 2026 or beyond.

The filing indicates that NewAmsterdam Pharma operates with European regulatory expertise and maintains collaborative relationships with established pharmaceutical partners capable of supporting large-scale market access initiatives. The company is incorporated in the Netherlands and maintains principal executive offices in Naarden, positioning it within the European regulatory and business environment. The immediate share price impact was not clear from available public information at the time of filing.

Warrant and Ordinary Share Trading Activity

NewAmsterdam Pharma's ordinary shares trade on NASDAQ under the ticker NAMS, while warrants to purchase ordinary shares trade under the ticker NAMSW. The filing confirms that both securities classes are registered on the Nasdaq Stock Market LLC. The company's ordinary shares have a nominal value of €0.12 per share according to the disclosed corporate structure. The filing does not provide current trading volumes, share price data, or warrant exercise information as of the July 24, 2026 announcement date.

Investors holding either ordinary shares or warrants in NewAmsterdam Pharma may view the positive European regulatory opinion as a material development supporting the company's pipeline value and potential future revenue generation. The announcement represents confirmation that at least one therapeutic program has advanced successfully through a critical regulatory checkpoint in a major market. The filing does not specify whether this positive opinion might trigger any contractual obligations, milestones, or payments under the Menarini Group partnership agreement.

Additional Disclosures and Exhibit Information

The company filed a press release issued on July 24, 2026, as Exhibit 99.1 to the current report. The press release provides the original announcement of the positive committee opinion and is incorporated by reference into the formal filing. This standard disclosure practice ensures that investors have access to the company's contemporaneous public statement regarding this regulatory development. The filing also includes an Inline XBRL cover page interactive data file as Exhibit 104, meeting SEC data standardization requirements.

The regulatory filing was signed by Mike Marino, identified as Chief Legal Officer of NewAmsterdam Pharma Company N.V., on July 24, 2026. The signature authenticates the accuracy and completeness of the disclosure under applicable securities law. Investors seeking more detailed information about the obicetrapib programs, clinical data, or partnership terms with Menarini Group should refer to the company's press release and any future regulatory filings that may contain additional details.